Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

The Lancet Haematology

Volumn 3, Issue 9, 2016, Pages e426-e436

  Cohen, Hannah ^a,b   Hunt, Beverley J ^b,d   Efthymiou, Maria ^b   Arachchillage, Deepa R J ^b   Mackie, Ian J ^b   Clawson, Simon ^c   Sylvestre, Yvonne ^c   Machin, Samuel J ^b   Bertolaccini, Maria L ^e   Ruiz Castellano, Maria ^d   Muirhead, Nicola ^c   Doré, Caroline J ^c   Khamashta, Munther ^d,f   Isenberg, David A ^a,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CREATININE CLEARANCE; EVALUATION AND FOLLOW UP; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD RENAL IMPAIRMENT; OUTCOME ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOSIS; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; EQUIVALENCE TRIAL (TOPIC); FOLLOW UP; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED KINGDOM;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; EQUIVALENCE TRIALS AS TOPIC; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE; RIVAROXABAN; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME; UNITED KINGDOM; WARFARIN;

EID: 84991661576     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)30079-5     Document Type: Article

References (35)

1. 1 Erkan, D, Aquiar, C, Andrade, D, et al. 14th International Congress in Antiphospholipid Antibodies Task Force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13 (2014), 685–696.
2. 2 Ruiz-Irastorza, G, Cuadrado, MJ, Ruiz-Arruza, I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20 (2011), 206–218.
3. 3 Ruiz-Irastorza, G, Egurbide, MV, Ugalde, J, Aguirre, C, High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 164 (2004), 77–82.
4. 4 Genetic and Rare Diseases Information Center (GARD). Antiphospholipid syndrome. https://rarediseases.info.nih.gov/gard/5824/antiphospholipid-syndrome/resources/1, May 25, 2016 (accessed July 11, 2016).
5. 5 Andreoli, L, Chighizola, CB, Banzato, A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 65 (2013), 1869–1873.
6. 6 Bayer. Xarelto 15mg & 20mg film-coated tablets. www.medicines.org.uk/emc/medicine/25591, May 18, 2016 (accessed July 11, 2016).
7. 7 Eichinger, S, Gregor, H, Kollars, M, Kyrle, PA, Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 54 (2008), 2042–2048.
8. 8 Conway, EM, Bauer, KA, Barzegar, S, Rosenberg, RD, Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 80 (1987), 1535–1544.
9. 9 Hemker, HC, Al Dieri, R, De Smedt, E, Béguin, S, Thrombin generation, a function test of the haemostatic-thrombotic system. J Thromb Haemost 96 (2006), 553–561.
10. 10 Brodin, E, Seljeflot, I, Arnesen, H, Hurlen, M, Applebom, H, Hansen, JB, Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res 123 (2009), 573–579.
11. 11 Gerotziafas, GT, Dupont, C, Spyropoulos, AC, Hatmi, M, Samama, MM, Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. Thromb Haemost 102 (2009), 42–48.
12. 12 Gerotziafas, GT, Elalamy, I, Depasse, F, Perzborn, E, Samama, MM, In vitro inhibition of thrombin generation, after tissue factor activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 5 (2007), 886–888.
13. 13 Green, L, Lawrie, AS, Patel, S, et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol 151 (2010), 469–476.
14. 14 Eerenberg, ES, Kamphuisen, PW, Sijpken, MK, Meijers, JC, Buller, HR, Levi, M, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossfover study in healthy subjects. Circulation 124 (2011), 1573–1579.
15. 15 Cohen, H, Doré, CJ, Clawson, S, et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 24 (2015), 1087–1094.
16. 16 Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
17. 17 Cockcroft, DW, Gault, H, Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976), 31–41.
18. 18 Winter, ME, Basic clinical pharmacokinetics, 4th edn., 2004, Lippincott Williams & Wilkins, Philadelphia.
19. 19 Keeling, D, Mackie, I, Moore, GW, Greer, IA, Greaves, M, British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 157 (2012), 47–58.
20. 20 Pengo, V, Tripodi, A, Reber, G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7 (2009), 1737–1740.
21. 21 Hochberg, M, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 40, 1997, 1725.
22. 22 Tripodi, A, Chantarangkul, V, Clerici, M, Negri, B, Galli, M, Mannucci, PM, Laboratory control of anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Br J Haematol 115 (2001), 672–678.
23. 23 Arachchillage, DR, Efthymiou, E, Mackie, IJ, Lawrie, AS, Machin, SJ, Cohen, H, Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res 135 (2015), 388–393.
24. 24 Dargaud, Y, Luddington, R, Gray, E, et al. Effect of standardisation and normalisation on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 135 (2007), 303–309.
25. 25 Efthymiou, M, Lawrie, AS, Mackie, I, et al. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. Thromb Res 135 (2015), 1191–1197.
26. 26 Cohen, H, Baglin, T, Plasma, plasma products and indications for their use. Contreras, M, (eds.) ABC of transfusion medicine, 4th edn., 2009, British Medical Journal Books (Wiley-Blackwell), 40–47.
27. 27 Dargaud, Y, Luddington, R, Gray, E, et al. Standardisation of thrombin generation test—which reference plasma for TGT? An international multicentre study. Thromb Res 125 (2010), 353–356.
28. 28 Kubitza, D, Becka, M, Voith, B, Zuehlsdorf, M, Wensing, G, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78 (2005), 412–421.
29. 29 Perzborn, E, Strassburger, J, Wilmen, A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost 3 (2005), 514–521.
30. 30 Gerotziafas, GT, Elalamy, I, Depasse, F, Perzborn, E, Samama, MM, In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 5 (2007), 886–888.
31. 31 Arachchillage, DRJ, Mackie, IJ, Efthymiou, M, Isenberg, DA, Machin, SJ, Cohen, H, Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 13 (2015), 1264–1273.
32. 32 Crowther, MA, Ginsberg, JS, Julian, J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. N Engl J Med 349 (2003), 1133–1138.
33. 33 Finazzi, G, Marchioli, R, Brancaccio, V, et al. A randomized clinical trial of high- intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 (2005), 848–943.
34. 34 Mueck, W, Lensing, AW, Agnelli, G, Decousus, H, Prandoni, P, Misselwitz, F, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50 (2011), 675–686.
35. 35 Pengo, V, Ruffatti, A, Legnani, C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8 (2010), 237–242.